Under Regulation (EU) 2017/746, specimen receptacles are deemed in vitro diagnostic (IVD) devices, so every evacuated tube in a European phlebotomy tray has carried IVD obligations since the rules became applicable on 26 May 2022, as the European Commission records. The venous blood test tubes market covers single-use tubes, evacuated or aspiration type, that receive venous blood with or without an additive and hold it until a laboratory runs the test. Douglas Insights sizes it at USD 2.64 billion in 2025: 15.42 billion tubes at an average realised price of USD 0.1712 each. Revenue then grows 3.72% a year to USD 3.80 billion by 2035, with volume doing most of the work. The study belongs to our in-vitro diagnostics coverage, and each step of the build follows the Douglas Insights research methodology.
Which companies supply the most venous blood test tubes, and how concentrated is the field?
Douglas Insights puts the top-three concentration in venous blood test tubes at 58.6% of 2025 value, led by BD with an estimated 36.9% share. Greiner Bio-One and Sarstedt follow, while Terumo, Streck, Hindustan Syringes and Medical Devices (HMD) and Chinese makers split the remaining 41.4%.
BD is the anchor. Its Specimen Management unit, home of the BD Vacutainer line, booked USD 1.87 billion in fiscal 2025, up 2.0% from USD 1.83 billion, with USD 981 million in the United States and USD 890 million abroad, according to BD’s fourth-quarter fiscal 2025 release. Douglas Insights estimates that tubes are 52% of that unit, about USD 973 million, because needles, holders, capillary and urine products sit in the same line. The release said fourth-quarter Vacutainer growth was partially offset by performance in China.
Greiner Bio-One, maker of VACUETTE tubes, generated about EUR 637 million in 2025 with 2,651 employees across 28 sites, per the Greiner Bio-One financial-year statement. Our model assigns roughly USD 324 million of that to venous tubes, a 12.3% share. Sarstedt, owner of the S-Monovette aspiration-and-vacuum system, employs about 3,000 people, runs over 13 production sites and keeps 90% of its value chain in-house; Douglas Insights estimates its venous tube revenue at USD 248 million, or 9.4%.
Terumo sells VENOJECT II venous tubes cleared by the US Food and Drug Administration (FDA) under product code JKA. Streck holds an FDA De Novo clearance for its Cell-Free DNA BCT tube when paired with the Guardant360 CDx liquid biopsy assay, and reported sales of more than 35 million tubes worldwide when that clearance was announced. HMD lists blood collection tubes, including its Vaku 8 line, and sells through more than 4,500 authorised dealers.
| Company | Venous tube brand | Built on | Douglas Insights 2025 share |
|---|---|---|---|
| BD | BD Vacutainer | USD 1.87 billion Specimen Management unit, US plant base | 36.9% |
| Greiner Bio-One | VACUETTE | EUR 637 million division, 28 sites | 12.3% |
| Sarstedt | S-Monovette | Over 13 plants, 90% in-house value chain | 9.4% |
| Terumo | VENOJECT II | 510(k) clearance under FDA product code JKA | Not split |
| Streck | Cell-Free DNA BCT | De Novo clearance, over 35 million tubes sold | Not split |
| HMD | Vaku 8 | Over 4,500 authorised dealers | Not split |
Where does a venous blood test tube end and capillary or culture kit begin in this study?
Venous blood test tubes are counted at 15.42 billion units in 2025, and the scope stops at the tube: needles, holders, capillary microtubes and culture bottles are excluded. Each tube is valued at the manufacturer’s realised price, so distributor margins and phlebotomy labour sit outside the USD 2.64 billion figure.
Two materials appear in the count. PET plastic tubes now dominate hospital laboratories and independent clinical laboratories in high-income markets because they survive pneumatic transport and do not shatter; glass tubes survive mainly in low-cost tenders and some coagulation work. Douglas Insights counts 86.4% of 2025 units as PET plastic tubes and 13.6% as glass tubes.
End users are split four ways. Hospital laboratories draw 52.7% of tubes, independent clinical laboratories 31.5%, blood banks 6.2% for donor screening samples, and physician offices 9.6%. Blood culture bottles are covered separately in our Blood Culture Bottle Market report.
Which additive type earns the most per venous blood test tube sold?
Serum separator and clot activator tubes lead venous blood test tube revenue with a 31.8% share, worth USD 839.5 million in 2025, because chemistry and immunoassay panels run on serum. Cell-free DNA and specialty tubes grow fastest, at 7.45% a year, as liquid biopsy volumes climb.
| Additive segment | Share 2025 | Value 2025 | CAGR 2026-2035 | Value 2035 |
|---|---|---|---|---|
| Serum separator and clot activator tubes | 31.8% | USD 839.5 million | 3.35% | USD 1.17 billion |
| EDTA tubes | 27.4% | USD 723.3 million | 3.55% | USD 1.03 billion |
| Lithium heparin plasma tubes | 17.3% | USD 456.7 million | 3.95% | USD 672.8 million |
| Sodium citrate coagulation tubes | 11.6% | USD 306.2 million | 2.85% | USD 405.6 million |
| Sodium fluoride glucose tubes | 4.9% | USD 129.4 million | 2.15% | USD 160.1 million |
| Cell-free DNA and specialty tubes | 7.0% | USD 184.8 million | 7.45% | USD 379.1 million |
Serum separator and clot activator tubes hold 31.8% because almost every routine metabolic, lipid and hormone panel needs clotted serum, and the gel barrier adds a few cents per tube. EDTA tubes take 27.4%, or USD 723.3 million, since full blood counts and HbA1c run on whole blood. Lithium heparin plasma tubes earn USD 456.7 million at 17.3%; emergency departments favour them because plasma skips the 30-minute clotting wait.
Sodium citrate coagulation tubes carry 11.6%, about USD 306.2 million, held back by the fill-volume precision that makes them costlier to make but limits their number per draw. Sodium fluoride glucose tubes are the smallest group at 4.9%, or USD 129.4 million, and grow only 2.15% because point-of-care meters replace some laboratory glucose work.
Cell-free DNA and specialty tubes are the fastest riser: USD 184.8 million today, USD 379.1 million by 2035. A stabilising tube sells for 20 to 50 times the price of a plain EDTA tube, so a 7.0% value share comes from well under 1% of units.
Why are venous blood test tube draw volumes still climbing at 3.10% a year?
Venous blood test tube volume rises 3.10% a year because four forces add draws: chronic-disease monitoring, Asian laboratory build-out, outpatient testing and molecular assays. Douglas Insights splits that volume leg into 1.25, 0.95, 0.50 and 0.40 percentage points, summing to the full 3.10.
Chronic-disease monitoring adds 1.25 points. Diabetes, renal and cardiometabolic patients are drawn several times a year, and each visit uses two or three venous blood test tubes. BD reports that its Vacutainer products care for 84 patients around the world every second, per its Sumter plant release, which our model converts into 2.65 billion BD draws a year. At 2.3 tubes a draw, that is 6.09 billion BD tubes, the anchor for the 15.42 billion global count.
Laboratory build-out in Asia Pacific adds 0.95 points. Hospital capacity and insurance coverage in India, Indonesia and Vietnam push routine panels into populations that rarely had venous draws a decade ago. Douglas Insights expects Asia Pacific tube units to rise from 6.38 billion in 2025 to well over 9 billion by 2035, the largest absolute gain of any region.
Outpatient and retail testing adds 0.50 points. Independent clinical laboratories open patient service centres in pharmacies and clinics, and every new draw site orders a stocked tray of venous tubes. BD’s US Specimen Management revenue rose 14.0% to USD 274 million in the quarter to 30 June 2026, while the nine-month US total grew 7.2% to USD 772 million, per BD’s third-quarter fiscal 2026 release dated 6 August 2026.
Molecular and liquid biopsy draws add 0.40 points. Cell-free DNA tubes let a sample travel to a central sequencing laboratory without immediate plasma separation, and Streck’s sale of more than 35 million such tubes shows that volume is real, not speculative. Each added oncology or prenatal screening draw uses one specialty tube worth several dollars.
BD is also adding capacity: it invested more than USD 90 million in its Sumter, South Carolina site since fiscal 2021 and plans about USD 30 million more in fiscal 2026. Suppliers do not fund plants for flat venous tube volume. Douglas Insights reckons the four drivers together lift global tube output from 15.42 billion in 2025 to 20.93 billion in 2035, an extra 5.51 billion venous blood test tubes a year by the end of the forecast.
Which headwinds keep venous blood test tube revenue below unit growth?
Three headwinds hold venous blood test tube revenue growth to 3.72% against much faster draw growth in Asia: Chinese procurement tenders, test-utilisation stewardship and IVDR certification cost. Together they remove about 0.90 points from the base case, and the legs already net them out.
Chinese volume-based procurement removes 0.45 points from the price leg. BD lists China’s volume-based procurement tender process among factors that can reduce demand or force lower prices, and its International Specimen Management revenue grew just 0.9% in fiscal 2025 to USD 890 million while US sales rose 3.0%.
Test-utilisation stewardship removes 0.30 points from volume. Hospitals cut duplicate panels and adopt smaller-volume venous tubes to reduce iatrogenic blood loss, which trims the tubes per draw from about 2.4 toward 2.2 in North America and Europe.
IVDR certification removes 0.15 points. Under Regulation (EU) 2024/1860 of 13 June 2024, class B devices and class A devices placed on the market in sterile condition must meet notified-body requirements by 31 December 2029. Smaller tube makers face audit and technical-file costs that a 0.1712-dollar product struggles to absorb.
Where do venous blood test tubes sell, region by region?
North America leads venous blood test tube revenue with USD 902.8 million in 2025, a 34.2% share, because its realised price per tube is the highest. Asia Pacific grows fastest, at 5.35% a year, as hospital laboratories multiply and draws per head rise.
North America reaches USD 1.21 billion by 2035 at 3.00% a year, supported by BD’s US manufacturing base and the shift toward retail draw sites. Europe holds USD 736.5 million, or 27.9%, and grows only 2.55% a year because draw volumes are mature and tenders cap prices; it reaches USD 947.4 million in 2035.
Asia Pacific starts at USD 755.0 million, a 28.6% share, and passes North America to reach USD 1.27 billion by 2035. Chinese tender prices keep its average venous tube price near USD 0.118, but its unit count grows faster than anywhere else. Latin America is worth USD 147.8 million and grows 4.10% to USD 220.9 million, led by Brazilian and Mexican private laboratories.
The Middle East and Africa is the wildcard: USD 97.8 million in 2025, rising 4.38% a year to USD 150.2 million. Gulf hospital programmes buy premium venous blood test tubes, while African volumes depend on donor-funded HIV and tuberculosis testing that can swing year to year.
How much does a laboratory pay per evacuated venous blood test tube?
A laboratory pays between USD 0.04 and USD 0.35 for a routine venous blood test tube in 2025, and Douglas Insights calculates the blended realised price at USD 0.1712. Specialty stabilising tubes sit far above that band, at USD 3.50 to USD 8.00 each.
Commodity plain and EDTA venous tubes from Chinese and Indian makers clear at USD 0.04 to USD 0.08 ex-works. European branded tubes sold into hospital tenders realise USD 0.12 to USD 0.22, while US group purchasing contracts for serum separator and plasma tubes run from USD 0.18 to USD 0.35. These bands are Douglas Insights estimates from the regional price per tube implied by our model, not list prices.
Average price rises 0.60% a year to USD 0.1818 by 2035. The mix shift toward cell-free DNA tubes adds price; Chinese tenders and private-label PET tubes subtract it.
How do IVDR rules and FDA classification govern venous blood test tubes?
Venous blood test tubes are regulated diagnostics on both sides of the Atlantic: the EU treats them as IVD specimen receptacles, and the FDA classes them as class II devices under 21 CFR 862.1675. Compliance cost therefore scales with the number of additive variants a maker sells.
In the EU, Regulation (EU) 2017/746 states that specimen receptacles shall be deemed in vitro diagnostic medical devices, whether vacuum-type or not. The 2024 amendment sets 31 December 2029 for class B and sterile class A legacy devices to complete notified-body certification, which matters for venous tube makers selling sterile-interior lines.
In the United States, blood collection tubes sit under FDA product code JKA, regulation 862.1675, as class II devices that reach the market through 510(k) clearance; Terumo’s VENOJECT II tubes are one cleared example. Stabilising tubes that claim a specific assay pairing, such as Streck’s, needed a De Novo route instead.
Glass or PET plastic: how is the venous tube material mix shifting?
PET plastic tubes account for 86.4% of venous blood test tube units in 2025, and Douglas Insights projects 91.2% by 2035 as glass tubes fade from hospital laboratories. Breakage, weight and pneumatic-tube transport all favour plastic.
Glass tubes keep 13.6% of units today, mostly in low-price tenders and in citrate work where some laboratories still prefer glass surface chemistry. Blood banks and physician offices adopted PET plastic tubes early because shipping glass from satellite sites raised breakage rates.
What did BD’s Waters transaction change for venous blood test tube supply?
BD kept its USD 1.87 billion Specimen Management unit, maker of Vacutainer venous blood test tubes, when it spun off Biosciences and Diagnostic Solutions into Waters on 9 February 2026. BD’s completion release describes the remaining company as a pure-play medical technology group, and the tube line now sits inside its Medical Essentials segment.
The deal valued the divested business at USD 18.8 billion and gave BD USD 4 billion in cash. For tube buyers the practical point is focus: Medical Essentials booked USD 1.68 billion in the quarter to 30 June 2026, and Specimen Management’s USD 511 million was up 8.7% from USD 470 million. Laboratory automation suppliers that sort and decap tubes are covered in our Clinical Lab Automation Market study.
What if Chinese tenders or liquid biopsy move faster: venous blood test tube scenarios to 2035?
Venous blood test tube revenue lands at USD 3.80 billion by 2035 in the base case, USD 3.35 billion in the slower case and USD 4.32 billion in the faster case. Volume growth is the swing factor, and the 3.72% base rate sits at the low end of published forecasts.
The base case runs 3.10% volume and 0.60% price. The slower case cuts volume to 2.20% and price to 0.20%, which is what wider Chinese tender pricing and tighter test stewardship in Europe would produce. The faster case lifts volume to 4.00% and price to 1.00%, driven by cell-free DNA screening and Asian laboratory build-out.
Sensitivity is asymmetric. Adding one point to annual tube growth lifts the 2035 total by USD 385.5 million; removing one point cuts it by USD 353.2 million. Published forecasts for blood and venous collection tubes span about 3.6% to 7.2% a year, and our figure sits near the bottom because it values tubes only, at realised prices.
The dated anchors move with the scenarios. BD’s 8.7% Specimen Management growth in the quarter reported on 6 August 2026 fits the faster case for the United States, while the 31 December 2029 IVDR deadline is the main European test for the slower case.
Douglas Exclusive: the Venous Tube Price-Intensity Index
The Venous Tube Price-Intensity Index is a Douglas Insights model, not an official statistic. It is built from 9 sourced inputs, including BD’s 84-patients-a-second figure, BD Specimen Management revenue for five reporting periods, Greiner Bio-One’s EUR 637 million and Streck’s 35 million tubes, plus 4 stated Douglas Insights assumptions.
The index divides each region’s modelled venous blood test tube revenue by its modelled tube count and scores the result against the global average price of USD 0.1712, set to 100.
| Region | Tubes 2025 (billion) | Price per tube (USD) | Index |
|---|---|---|---|
| North America | 3.86 | 0.234 | 137 |
| Europe | 3.58 | 0.206 | 120 |
| Asia Pacific | 6.38 | 0.118 | 69 |
| Latin America | 0.97 | 0.152 | 89 |
| Middle East and Africa | 0.63 | 0.155 | 91 |
The finding is stark. Asia Pacific draws 41.4% of the world’s venous tubes but earns 28.6% of the value, scoring 69, while North America scores 137. Every point of unit share that moves east lowers the global average price, which is why the price leg stays at 0.60% even as specialty tubes gain.
How we count 15.42 billion venous blood test tubes and check the total?
Douglas Insights counts 15.42 billion venous blood test tubes in 2025 across 5 regions and 6 additive segments, from 9 sourced inputs and 4 assumptions. Our arithmetic is direct: 15.42 billion tubes times USD 0.1712 equals USD 2.64 billion.
Step one: 84 BD patients a second times 31,536,000 seconds gives 2.65 billion draws. Step two: 2.3 tubes per draw gives 6.09 billion BD tubes. Step three: a 39.5% BD unit share gives 15.42 billion global tubes. Cross-check one: tubes at 52% of BD’s USD 1.87 billion Specimen Management revenue give USD 973 million, a 36.9% value share, within 2.6 points of the unit share. Cross-check two: published 2025 estimates for broader blood collection tubes run to USD 3.6 billion, so a tubes-only USD 2.64 billion figure is consistent.
Douglas Insights analysts drafted this study with AI assistance and checked every sourced figure against the linked primary pages. Related purification steps after the draw are covered in our Magnetic Bead-based Nucleic Acid Extraction Market report.
Which end users draw the most venous blood test tubes?
Hospital laboratories draw 52.7% of venous blood test tubes, about 8.13 billion units in 2025, because inpatients and emergency patients are drawn daily. Independent clinical laboratories follow at 31.5%, and they grow fastest at about 4.2% a year in units.
Physician offices use 9.6% of tubes, roughly 1.48 billion, mostly for samples sent to reference laboratories. Blood banks take 6.2%, about 0.96 billion tubes, for donor screening and typing, a share tied to collection volumes rather than disease testing.
How this report is built
- Every figure carries a confidence grade in the fact sheet above, and the working model ships with every licence.
- Five regional models sum to the global figure, with country tables in the Excel model.
- The next scheduled review of this study is April 2027.
- Licence holders receive it as a maintained tab in the Excel model.
Sources
- EUR-Lex Regulation (EU) 2017/746 on in vitro diagnostic medical devices (2017)
- European Commission New regulations: IVDR applicable 26 May 2022 (2022)
- EUR-Lex Regulation (EU) 2024/1860 amending IVDR transitional provisions (2024)
- BD via SEC EDGAR BD fourth quarter and full year fiscal 2025 results (Exhibit 99.1) (2025)
- BD via SEC EDGAR BD third quarter fiscal 2026 results (Exhibit 99.1) (2026)
- BD via SEC EDGAR BD completes combination of Biosciences and Diagnostic Solutions with Waters (2026)
- BD BD celebrates 55 years of manufacturing in Sumter, S.C. (2025)
- US FDA 510(k) K900309 VENOJECT II blood collection tubes (1990)
- US FDA Product classification JKA, 21 CFR 862.1675 (2026)
- Greiner Bio-One Financial year 2025 (2026)
- Sarstedt About us (2026)
- Streck Cell-Free DNA BCT receives U.S. FDA De Novo clearance (2020)
- Hindustan Syringes and Medical Devices About HMD (2026)
Inside the 186-page report
01Executive summary12 sections
The market in one view
- 1.1Market snapshot, 2025 and 2035
- 1.1.1Market size, 2025
- 1.1.2Forecast, 2035
- 1.1.3Growth rate, 2026–2035
- 1.2Growth decomposition
- 1.2.1Volume growth (billion tubes)
- 1.2.2Value per unit growth
- 1.3Key findings
- 1.4Segment highlights
- 1.5Regional highlights
- 1.6Competitive highlights
- 1.7Douglas Insights verdict
02Scope and definitions17 sections
What counts as a venous blood test tube here
- 2.1Market definition
- 2.2Inclusions and exclusions
- 2.2.1Inclusions
- 2.2.2Exclusions
- 2.2.3Materials
- 2.3Segmentation
- 2.3.1By additive
- 2.3.2By material
- 2.3.3By end user
- 2.3.4By region
- 2.4Years considered
- 2.4.1Base year 2025
- 2.4.2Forecast 2026–2035
- 2.5Currency and units
- 2.5.1Value in USD million
- 2.5.2Volume in billion tubes
- 2.6Who this report is for
03Research methodology16 sections
Bottom-up: billion tubes × value per unit
- 3.1Bottom-up market model
- 3.1.1Volume base, 2025 (billion tubes)
- 3.1.2Value per unit
- 3.1.3Forecast legs to 2035
- 3.2Top-down cross-checks
- 3.3Data triangulation
- 3.4Sources
- 3.4.1Regulators and statistics offices
- 3.4.2Company filings and results
- 3.4.3Trade and industry bodies
- 3.4.413 primary sources cited
- 3.5Confidence grading
- 3.6Assumptions and limitations
- 3.6.1Build steps
- 3.6.2Cross-checks
- 3.6.3AI disclosure
04Volume drivers3 sections
Four drivers in percentage points
- 4.1Chronic disease
- 4.2Asian build-out
- 4.3Outpatient and molecular
05Restraints3 sections
Tenders, stewardship, IVDR
- 5.1China procurement
- 5.2Stewardship
- 5.3Certification cost
06Pricing3 sections
Realised price bands per tube
- 6.1Commodity tubes
- 6.2Branded tenders
- 6.3Specialty tubes
07Regulation3 sections
IVDR and FDA classification
- 7.1Specimen receptacles
- 7.22029 deadline
- 7.3510(k) and De Novo
08Materials3 sections
PET plastic versus glass
- 8.1Unit split
- 8.22035 shift
- 8.3Use cases
09Recent developments3 sections
BD and Waters transaction
- 9.1Medical Essentials
- 9.2Quarterly results
- 9.3Supply focus
10End users3 sections
Hospitals, laboratories, blood banks, offices
- 10.1Unit split
- 10.2Growth
- 10.3Drivers
11Market size and forecast, 2025–20355 sections
Global value, volume and value per unit
- 11.1Market value, 2025–2035
- 11.2Volume (billion tubes), 2025–2035
- 11.3Value per unit, 2025–2035
- 11.4Year-on-year growth
- 11.5Growth decomposition
12Venous Blood Test Tubes market, by additive19 sections
6 segments, value 2025–2035
- 12.1Overview and share, 2025 and 2035
- 12.2Serum separator and clot activator tubes
- 12.2.1Market size and forecast, 2025–2035
- 12.2.2Growth outlook
- 12.3EDTA tubes
- 12.3.1Market size and forecast, 2025–2035
- 12.3.2Growth outlook
- 12.4Lithium heparin plasma tubes
- 12.4.1Market size and forecast, 2025–2035
- 12.4.2Growth outlook
- 12.5Sodium citrate coagulation tubes
- 12.5.1Market size and forecast, 2025–2035
- 12.5.2Growth outlook
- 12.6Sodium fluoride glucose tubes
- 12.6.1Market size and forecast, 2025–2035
- 12.6.2Growth outlook
- 12.7Cell-free DNA and specialty tubes
- 12.7.1Market size and forecast, 2025–2035
- 12.7.2Growth outlook
13Venous Blood Test Tubes market, by material7 sections
2 segments, value 2025–2035
- 13.1Overview and share, 2025 and 2035
- 13.2PET plastic tubes
- 13.2.1Market size and forecast, 2025–2035
- 13.2.2Growth outlook
- 13.3Glass tubes
- 13.3.1Market size and forecast, 2025–2035
- 13.3.2Growth outlook
14Venous Blood Test Tubes market, by end user13 sections
4 segments, value 2025–2035
- 14.1Overview and share, 2025 and 2035
- 14.2Hospital laboratories
- 14.2.1Market size and forecast, 2025–2035
- 14.2.2Growth outlook
- 14.3Independent clinical laboratories
- 14.3.1Market size and forecast, 2025–2035
- 14.3.2Growth outlook
- 14.4Blood banks
- 14.4.1Market size and forecast, 2025–2035
- 14.4.2Growth outlook
- 14.5Physician offices
- 14.5.1Market size and forecast, 2025–2035
- 14.5.2Growth outlook
15Regional analysis26 sections
5 regions
- 15.1Regional overview and share, 2025 and 2035
- 15.2North America
- 15.2.1Market size and forecast, 2025–2035
- 15.2.2By additive
- 15.2.3By material
- 15.2.4By end user
- 15.3Europe
- 15.3.1Market size and forecast, 2025–2035
- 15.3.2By additive
- 15.3.3By material
- 15.3.4By end user
- 15.4Asia Pacific
- 15.4.1Market size and forecast, 2025–2035
- 15.4.2By additive
- 15.4.3By material
- 15.4.4By end user
- 15.5Latin America
- 15.5.1Market size and forecast, 2025–2035
- 15.5.2By additive
- 15.5.3By material
- 15.5.4By end user
- 15.6Middle East and Africa
- 15.6.1Market size and forecast, 2025–2035
- 15.6.2By additive
- 15.6.3By material
- 15.6.4By end user
16Competitive landscape10 sections
6 companies profiled
- 16.1Market concentration
- 16.2Market share analysis, 2025
- 16.3Strategic moves: acquisitions, launches, contracts
- 16.4Company profilesEach profile: overview, products, financials where reported, position in this market, recent developments
- 16.4.1BD
- 16.4.2Greiner Bio-One
- 16.4.3Sarstedt
- 16.4.4Terumo
- 16.4.5Streck
- 16.4.6HMD
17Scenarios to 20355 sections
Base, slower, faster
- 17.1Slower case
- 17.2Base case case
- 17.3Faster case
- 17.4Sensitivity of the 2035 value
- 17.5Published forecasts compared
18Douglas Exclusive: the Venous Tube Price-Intensity Index3 sections
Regional price per tube against a global 100
- 18.1Inputs
- 18.2Scores
- 18.3Finding
19Appendix5 sections
Data, sources and licence
- 19.1Data tables (Excel model)
- 19.2Sources (13)
- 19.3Abbreviations
- 19.4Change log and next review
- 19.5Licence and how to cite
TList of tables37
- Table 1Market value, 2025–2035 (USD million)
- Table 2Volume, 2025–2035 (billion tubes)
- Table 3Value per unit, 2025–2035
- Table 4Venous Blood Test Tubes market by additive, 2025–2035 (USD million)
- Table 5Serum separator and clot activator tubes: market size, 2025–2035 (USD million)
- Table 6EDTA tubes: market size, 2025–2035 (USD million)
- Table 7Lithium heparin plasma tubes: market size, 2025–2035 (USD million)
- Table 8Sodium citrate coagulation tubes: market size, 2025–2035 (USD million)
- Table 9Sodium fluoride glucose tubes: market size, 2025–2035 (USD million)
- Table 10Cell-free DNA and specialty tubes: market size, 2025–2035 (USD million)
- Table 11Venous Blood Test Tubes market by material, 2025–2035 (USD million)
- Table 12PET plastic tubes: market size, 2025–2035 (USD million)
- Table 13Glass tubes: market size, 2025–2035 (USD million)
- Table 14Venous Blood Test Tubes market by end user, 2025–2035 (USD million)
- Table 15Hospital laboratories: market size, 2025–2035 (USD million)
- Table 16Independent clinical laboratories: market size, 2025–2035 (USD million)
- Table 17Blood banks: market size, 2025–2035 (USD million)
- Table 18Physician offices: market size, 2025–2035 (USD million)
- Table 19Venous Blood Test Tubes market by region, 2025–2035 (USD million)
- Table 20North America: market by additive, 2025–2035 (USD million)
- Table 21North America: market by material, 2025–2035 (USD million)
- Table 22North America: market by end user, 2025–2035 (USD million)
- Table 23Europe: market by additive, 2025–2035 (USD million)
- Table 24Europe: market by material, 2025–2035 (USD million)
- Table 25Europe: market by end user, 2025–2035 (USD million)
- Table 26Asia Pacific: market by additive, 2025–2035 (USD million)
- Table 27Asia Pacific: market by material, 2025–2035 (USD million)
- Table 28Asia Pacific: market by end user, 2025–2035 (USD million)
- Table 29Latin America: market by additive, 2025–2035 (USD million)
- Table 30Latin America: market by material, 2025–2035 (USD million)
- Table 31Latin America: market by end user, 2025–2035 (USD million)
- Table 32Middle East and Africa: market by additive, 2025–2035 (USD million)
- Table 33Middle East and Africa: market by material, 2025–2035 (USD million)
- Table 34Middle East and Africa: market by end user, 2025–2035 (USD million)
- Table 35Company market shares, 2025
- Table 36Scenario values, 2035
- Table 37Sources and confidence grades by figure
FList of figures9
- Figure 1Market value, 2025–2035
- Figure 2Growth decomposition, 2026–2035
- Figure 3Share by additive, 2025 and 2035
- Figure 4Share by material, 2025 and 2035
- Figure 5Share by end user, 2025 and 2035
- Figure 6Share by region, 2025 and 2035
- Figure 7Growth by region, 2026–2035
- Figure 8Market concentration, 2025
- Figure 9Scenario paths to 2035
Questions buyers ask
What is a venous blood test tube worth to its maker on average?
USD 0.1712 per tube in 2025, the blended realised price across 15.42 billion tubes, rising to USD 0.1818 by 2035.
What revenue do venous blood test tubes generate in 2025 and 2035?
USD 2.64 billion in 2025, rising to USD 3.80 billion by 2035 at 3.72% a year, with 3.10 points from volume and 0.60 from price.
How much of the venous tube market does BD hold?
36.9% share in 2025 by Douglas Insights estimate, about USD 973 million, taken as 52% of BD's USD 1.87 billion Specimen Management revenue.
Which additive tube earns the most revenue?
31.8% of 2025 value goes to serum separator and clot activator tubes, USD 839.5 million, because chemistry and immunoassay panels run on serum.
Why do cell-free DNA tubes outgrow routine venous tubes?
7.45% a year is the cell-free DNA and specialty tube growth rate, because liquid biopsy samples must travel to central laboratories without immediate plasma separation.
Which region draws the most tubes but earns the least per tube?
41.4% of global venous tube units come from Asia Pacific, which scores 69 on the Douglas Insights price-intensity index against 137 for North America.
When must sterile class A venous tubes meet IVDR notified-body rules?
31 December 2029 is the deadline Regulation (EU) 2024/1860 sets for class B devices and class A devices placed on the market in sterile condition.
What happens to the 2035 figure if tube growth shifts by one point?
USD 385.5 million is added by one extra point of annual tube growth, while one point less removes USD 353.2 million from the USD 3.80 billion base.
Research & citation
This report was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.
Douglas Insights Inc (2026). Venous Blood Test Tubes Market. Report DI-HC-10701, October 2026. https://www.douglasinsights.com/venous-blood-test-tubes-market/